Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the SMART-EXAM (SMart Angioplasty Research Team-Pragmatic Randomized Trial for Comparing Routine versus As-Needed EXercise or Pharmacologic Stress Testing in Asymptomatic Patients with High-Risk Coronary CalciuM) trial is to compare the major adverse cardiovascular events between routine stress testing and as-needed stress testing in asymptomatic patients with high-risk coronary calcium (Agatston Score ≥ 400) without proven ASCVD.
The coronary artery calcium (CAC) scan, a marker of subclinical coronary atherosclerosis, has become popular for individuals at risk for atherosclerotic cardiovascular disease. CAC is strongly associated with atherosclerotic burden and predicts coronary heart disease events and mortality, regardless of their age, sex, race, or atherosclerotic cardiovascular disease (ASCVD) risk. Furthermore, the progression of CAC is associated with an increased risk for future hard and total coronary heart disease events. The use of CAC scoring was associated with significant improvements in the reclassification and discrimination of incident ASCVD. Nevertheless, the current guidelines recommend CAC measurement for selected cases only with borderline or intermediate risk of ASCVD. However, in real-world practice, CAC testing is increasingly being promoted to the public as a means of self-assessment of cardiovascular risk and is widely being used regardless of ASCVD risk.
Non-invasive stress testing is often recommended to exclude potentially dangerous coronary artery disease. However, stress testing in asymptomatic individuals has low sensitivity and specificity.9 Although the 2019 Primary Prevention of Cardiovascular Disease Guidelines do not comment on functional or invasive testing in asymptomatic individuals with a high CAC score, the 2009 Appropriate Use Criteria for Cardiac Radionuclide Imaging report gives a level A recommendation for obtaining a stress test in asymptomatic individuals with CAC score ≥400.10 In addition, the 2013 update of the 2009 document also considers stress imaging appropriate for patients with CAC score >100. However, there have been no large randomized controlled trials or observational studies that have evaluated the utility of functional or invasive testing in asymptomatic individuals free of ASCVD with high CAC scores. Theoretically, early detection and revascularization of ischemia producing lesions in asymptomatic patients with high-risk coronary calcification without proven ASCVD might reduce the future risk of major adverse cardiovascular events.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Routine stress testing | Experimental | In this group, the preselected functional stress testing (exercise electrocardiography, stress echocardiography, nuclear imaging, or stress cardiac magnetic resonance imaging) will be performed within three months (± 2 months) according to the practice pattern of each participating center. |
|
| As-needed stress testing | Active Comparator | In this group, optimal medical treatment will be performed by current guidelines without further testing. A stress test will be performed only when new symptoms (exertional chest pain or dyspnea) occur that may clinically suggest significant coronary artery disease. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Non-invasive stress test | Diagnostic Test | Nuclear imaging, stress echocardiography, exercise electrocardiography, stress cardiac magnetic resonance imaging |
|
| Measure | Description | Time Frame |
|---|---|---|
| Occurrence of major adverse cardiovascular events | a composite of death from cardiovascular causes, myocardial infarction, unplanned hospitalization leading to an urgent revascularization procedure, or heart failure hospitalization | up to 4.5 years of median follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| cardiovascular death | death from cardiovascular causes | up to 4.5 years of median follow-up |
| myocardial infarction | myocardial infarction |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Documentation of objective evidence of inducible ischemia before enrollment
Presence of significant coronary artery stenosis (≥ 70% diameter stenosis) confirmed by coronary angiography or coronary computed tomography angiography before enrollment
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Seung-Hyuk Choi, MD | Contact | 82-2-3410-3419 | sh1214.choi@samsung.com | |
| Ki Hong Choi | Contact | 82-2-3410-6653 | cardiokh@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Seung-Hyuk Choi, MD | Samsung Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| SamsungMedicalCenter | Recruiting | Seoul | 06351 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Medical treatment without further testing | Diagnostic Test | Optimal medical treatment for primary prevention. |
|
| up to 4.5 years of median follow-up |
| unplanned hospitalization leading to an urgent revascularization procedure | unplanned hospitalization leading to an urgent revascularization procedure | up to 4.5 years of median follow-up |
| heart failure hospitalization | heart failure hospitalization | up to 4.5 years of median follow-up |
| all-cause death | death from any causes | up to 4.5 years of median follow-up |
| a composite of death from cardiovascular cause or myocardial infarction | a composite of death from cardiovascular cause or myocardial infarction | up to 4.5 years of median follow-up |
| any hospitalization | any hospitalization | up to 4.5 years of median follow-up |
| performing revascularization procedure | performing revascularization procedure | up to 4.5 years of median follow-up |
| performing invasive coronary angiography procedure | performing invasive coronary angiography procedure | up to 4.5 years of median follow-up |
| stroke | stroke | up to 4.5 years of median follow-up |
| bleeding | Bleeding Academic Research Consortium type 2-5 | up to 4.5 years of median follow-up |
| total medical cost | total medical cost | up to 4.5 years of median follow-up |